Safety Study of Gene Therapy for Ischemic Heart Disease in Korea (Engensis)
Open-label, Non-comparative, Dose-escalation, Single-center, Phase 1 Trial to Evaluate the Safety of VM202RY Gene Medicine Injected Into Cardiac Muscle of Incompletely Revascularized Area After CABG in Patients With Ischemic Heart Diseases
Sponsor: Helixmith Co., Ltd.
A PHASE1/PHASE2 clinical study on Ischemic Heart Disease, this trial is completed. The trial is conducted by Helixmith Co., Ltd. and has accumulated 10 data snapshots since 2007. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.
Status Flow
Change History
10 versions recorded-
Nov 2025 — Present [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1 → PHASE1/PHASE2
-
Sep 2025 — Nov 2025 [monthly]
Completed PHASE1
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
▶ Show 5 earlier versions
-
Nov 2019 — Jan 2021 [monthly]
Completed PHASE1
-
Jun 2019 — Nov 2019 [monthly]
Completed PHASE1
-
Jun 2018 — Jun 2019 [monthly]
Completed PHASE1
-
Feb 2018 — Jun 2018 [monthly]
Completed PHASE1
-
Jan 2017 — Feb 2018 [monthly]
Completed PHASE1
First recorded
Jan 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Helixmith Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .